Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,073 | -3,053 | -1,019 | -2,047 | -754 |
| Depreciation Amortization | 73 | 48 | 23 | 3,727 | 2,467 |
| Accounts receivable | N/A | N/A | N/A | -248 | 222 |
| Other Working Capital | -1,532 | -1,097 | -900 | -37 | -270 |
| Other Operating Activity | 68 | 46 | 23 | 1,349 | 96 |
| Operating Cash Flow | $-6,463 | $-4,057 | $-1,873 | $2,744 | $1,761 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -26 | -26 | -5 | -1,065 | -964 |
| Investing Cash Flow | $-26 | $-26 | $-5 | $-1,065 | $-964 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 310 | 310 | N/A | N/A | 0 |
| Debt Repayment | N/A | N/A | N/A | -1,045 | -789 |
| Common Stock Issued | 3,859 | 3,859 | 313 | N/A | N/A |
| Dividend Paid | N/A | N/A | N/A | -16 | -8 |
| Other Financing Activity | 275 | 0 | 0 | -37 | -29 |
| Financing Cash Flow | $4,444 | $4,169 | $313 | $-1,098 | $-826 |
| Exchange Rate Effect | N/A | N/A | N/A | 42 | 27 |
| Beginning Cash Position | 5,101 | 5,101 | 5,101 | 2,786 | 2,786 |
| End Cash Position | 3,055 | 5,187 | 3,536 | 3,409 | 2,784 |
| Net Cash Flow | $-2,046 | $86 | $-1,565 | $623 | $-2 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,463 | -4,057 | -1,873 | 2,744 | 1,761 |
| Capital Expenditure | -26 | -26 | -5 | -1,094 | -993 |
| Free Cash Flow | -6,490 | -4,083 | -1,878 | 1,650 | 768 |